Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of rilzabrutinib in immune thrombocytopenia (ITP), sponsored by Sanofi. Started Oct 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07007962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007962.